Mar. 13 at 6:13 AM
$RGNX
IDK the more I look at this data the more I like it, maybe I'm delusional. The conversation is really gonna begin shifting imo to 2 and 3 year results, that's where this thing potentially establishes dominance.
Using Elevidys as a proxy the treatment is only increasing NSAA by .77 at the mean age of 9, which is basically the mean age Regenx dosed at for phase 1/2. Despite this later dosing RGX-202 is showing NSAA gains of 2-3 at 12 months. This even extends to the older dose level 1 patients. Obviously it's pretty hard to do a 1-1 as we're talking about 10 patients on 202's side and 50 patients on Elevidy's side, still very promising.
I'll be super interested in seeing if the decline in the one patient that was dosed above 10 levels out at 18 and 24 months, no therapy is 100% effective but one thing I liked about the 18 month data drop is that the decliner in that one leveled out.
